Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study. [electronic resource]
Producer: 20190924Description: 989-999 p. digitalISSN:- 1532-6535
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Immunological -- administration & dosage
- Brentuximab Vedotin
- Child
- Clinical Trials, Phase III as Topic
- Computer Simulation
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Dosage Calculations
- Drug Monitoring
- Female
- Humans
- Immunoconjugates -- administration & dosage
- Lymphoma, T-Cell, Cutaneous -- blood
- Male
- Middle Aged
- Models, Biological
- Progression-Free Survival
- Risk Assessment
- Skin Neoplasms -- blood
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.